METROPOLIS

Metropolis Healthcare Ltd.
Registered Office: 4th Floor, East Wing, Plot-254 B, Nirlon House, Dr. Annie Besant Rd, Worli, Mumbai - 400030, Maharashtra, India.
Corporate Office & Global Reference Laboratory:
4th Floor, Commercial Bldg-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070. CIN: L73100MH2000PLC192798.

Ref: MHL/Sec&Legal/2026-27/58 **November 03, 2026**

To,
BSE Limited
Scrip Code: 542650

National Stock Exchange of India Limited
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is the Press Release as mentioned below:

"Metropolis Healthcare reports strong Q2 FY27 performance, with revenue up 16% to ₹497 crore and PAT up 43% to ₹75 crore."

You are requested to take the above information on record.

Thanking you,
Yours faithfully,

For **Metropolis Healthcare Limited**

Kamlesh Chandrashekhar Kulkarni

Digitally signed by Kamlesh Chandrashekhar Kulkarni
DN: c=IN, st=Maharashtra, 2.5.4.20=7b2c375c9b619b9bcfca3000f2fbd0e3a8a7775221bd4075c136f7c37ee654 1, postalCode=422004, street=SO Chandrashekhar Kulkarni Plot No47 Vrundavan Nagar Dindori Road Near Gajanan Maharaj Mandir Mhasrul Nashik, pseudonym=ce57b9d646ce4631a4e68e0e138a62c3, title=1552, serialNumber=2d0fa0037beae42820275c8effcf3ae2073aa3f9ef35e80715cbcb9b2acf dcc68, o=Personal, cn=Kamlesh Chandrashekhar Kulkarni
Date: 2026.11.03 19:06:39 +05'30'

Kamlesh C Kulkarni
Head – Legal & Secretarial

Encl.: a/a

PRESS RELEASE

Metropolis Healthcare reports strong Q2 FY27 performance, with revenue up 16% to ₹497 crore and PAT up 43% to ₹75 crore.

Mumbai, India, 3rd November 2026: Ameera Shah-led Metropolis Healthcare Limited (NSE: METROPOLIS | BSE: 542650), one of India's leading diagnostic chains, today announced its unaudited consolidated financial results for the quarter ended 30th September 2026.

REVENUE	EBITDA	PAT
INR 497 Cr	INR 135 Cr	INR 75 Cr
▲ 16% YoY	▲ 24% YoY	▲ 43% YoY

Q2 FY27 – Financial & Operational Highlights

- **Patient volume grew 10% YoY to 4.1 million**, while **test volume increased 11% YoY to 8.7 million**, reflecting sustained demand and the continued shift towards organised diagnostic providers.
- **B2C revenue grew 17% YoY to INR 289 crore,** driven by lifecycle-led customer engagement, targeted micro-marketing initiatives and strong brand recall. **B2B revenue rose 15% YoY to INR 208 crore,** driven by the addition of new clients and increased uptake of specialised tests among existing clients.
- **TruHealth revenue grew 20% YoY to INR 86 crore**, driven by premiumisation and more customers opting for preventive care. **Specialty revenue rose 20% YoY to INR 198 crore**, led by advanced genomic testing and accelerated growth in cancer testing.
- **Revenue per Patient (RPP) increased 6% YoY to INR 1,221 d**espite no price increase benefit, **while Revenue per Test (RPT) improved 5% YoY to INR 572,** supported by a richer test mix and improved realisations.
- **Tier III cities remained the fastest-growing markets**, with revenue rising around 20% YoY. Metropolis now reaches around 750 towns through 5,119 service points.
- The Board has declared an interim dividend of ₹1 per share.

"We are pleased with our H1FY27 performance, with revenue up 16% and no price increase, reflecting the trust of patients and clinicians. As diagnostics becomes central to preventive and precision healthcare, we are building Metropolis into a stronger, differentiated and future-ready platform. We will deepen our science and genomics expertise, use technology to transform the patient experience, and pursue strategic acquisitions that sharpen our competitive edge. From a 1,000-gene oncology panel to a blood-based Alzheimer's test, our newest offerings bring earlier answers to complex clinical questions. Under Metropolis 3.0, our priority is not simply to expand our footprint, but to create the capabilities that will define the next phase of Indian diagnostics."
~ Ms. Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited.

"Q2FY27 was a strong quarter, with EBITDA up 24% and margin expanding 180 basis points to 27.2%, reflecting steadily improving operating performance. PAT was up 43%, supported by gains across B2C, B2B, TruHealth and Specialty, higher test volumes and a wider network. For the rest of the year, we will extend our presence in Tier II and III towns, where demand is rising fastest, scale our wellness and specialty portfolio, and broaden engagement with doctors and hospitals. Disciplined execution and greater productivity will remain central to sustaining this growth."
~ Mr. Surendran Chemmenkotil, Managing Director, Metropolis Healthcare Limited.

Financial Results Snapshot – Consolidated						
Particulars (Amounts in ₹ crore)	**Q2 FY27**	**Q2 FY26**	**Y-o-Y**	**H1 FY27**	**H1 FY26**	**Y-o-Y**
Revenue from Operations	496.8	429.2	15.8%	947.0	815.3	16.2%
Reported EBITDA	134.9	108.9	23.9%	248.2	198.0	25.3%
Reported EBITDA Margin (%)	27.2%	25.4%	+180 bps	26.2%	24.3%	+190 bps
Profit Before Tax (PBT)	102.5	71.0	44.4%	180.2	132.3	36.2%
Profit After Tax (PAT)	75.5	52.9	42.7%	132.4	98.1	34.9%
PAT Margin (%)	15.2%	12.3%	+290 bps	14.0%	12.0%	+200 bps

About Metropolis Healthcare Limited: Established in 1981, Metropolis Healthcare Limited is one of India's leading diagnostic chains, led by visionary leader Ms. Ameera Shah. With over four decades of excellence, Metropolis has been a pioneer in delivering best-in-class diagnostic services to patients, healthcare providers, and corporates across India and Africa. The company's extensive footprint spans 28 states, 7 Union Territories, and over 750+ towns in India, supported by a robust network of more than 213 laboratories, 5119 plus service network, and over 10,000 touchpoints. Each year, Metropolis serves millions of individuals by providing actionable health insights that empower better clinical outcomes.

Metropolis offers a comprehensive range of more than 4,500 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. The company's commitment to quality and accuracy is reinforced by its consistent CAP proficiency score of over 99.99% for the past decade, placing it among the top 1% of laboratories worldwide for quality assurance. The Metropolis philosophy is built on the pillars of technological superiority, a warm, patient-centric approach, and reliable diagnostic reports. For more information, please visit www.metropolisindia.com or click on Twitter, Facebook, or LinkedIn

Safe harbor statement: Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details, please contact:

Company: Metropolis Healthcare Ltd.

CIN: L73100MH2000PLC192798
Mr. Jeyasingh Balakrishnan
Head – Corporate Communications & CSR
+91 9833836185
Email: jeyasingh.b@metropolisindia.com

Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285
Mr. Shogun Jain / Mr. Sagar Shroff
+91 77383 77756 / +91 98205 19303
Email: shogun.jain@sgapl.net/
sagar.shroff@sgapl.net